An Open Trial to Assess the Tolerability of AVANZ Cupressus Immunotherapy
Phase of Trial: Phase II
Latest Information Update: 27 Feb 2015
Price : $35 *
At a glance
- Drugs Cupressus arizonica pollen allergy immunotherapy (Primary)
- Indications Allergic rhinoconjunctivitis
- Focus Adverse reactions
- Sponsors ALK-Abello
- 05 Jan 2015 Status changed from recruiting to completed, as reported by ClinicalTrials.gov record.
- 16 Jun 2014 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov record.
- 03 Mar 2014 New trial record